Skip to Main Content

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Conditions

Diseases of the Cardiovascular System

What is the purpose of this trial?

This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).

  • Trial with
    Yale University School of Medicine
  • Start Date
    06/03/2021
  • End Date
    12/31/2025

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/08/2022
  • Study HIC
    #2000028712